The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
Journal of Scleroderma and Related Disorders · 2020-02 · 5 (1) · 40-50
DOI: 10.1177/2397198319865367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Scleroderma and Related Disorders, online erschienen am 07.08.2019. Verfasst von Wenxia Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Scleroderma Program, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Scleroderma Foundation.
Abstract (Originalsprache)
Rationale
Fibrosis leads to failure of the skin, lungs, and other organs in systemic sclerosis; accounts for substantial morbidity and mortality; and lacks effective therapy. Myofibroblast activation underlies organ fibrosis, but the key extracellular cues driving persistence of the process remain incompletely characterized.
Objectives
The objectives were to evaluate activation of the IL6/JAK/STAT axis associated with fibrosis in skin and lung biopsies from systemic sclerosis patients and effects of the Food and Drug Administration–approved JAK/STAT inhibitor, tofacitinib, on skin and lung fibrosis in animal models.
Methods
Bioinformatic analysis showed that IL6/JAK/STAT3 and tofacitinib gene signatures were aberrant in biopsies from systemic sclerosis patients in four independent cohorts. The results were confirmed by JAK and STAT3 phosphorylation in both skin and lung biopsies from patients with systemic sclerosis. Furthermore, treatment of mice with the selective JAK inhibitor tofacitinib not only prevented bleomycin-induced skin and lung fibrosis but also reduced skin fibrosis in TSK1/+ mice.
Conclusion
These findings implicate the JAK/STAT pathway in systemic sclerosis skin and lung fibrosis and identify tofacitinib as a potential antifibrotic agent for the treatment of systemic sclerosis and other fibrotic diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Northwestern Scleroderma Program, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Surgical Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
ORCID-Profile: Swati Bhattacharyya
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Scleroderma Foundation
- pfizer
Zitieren
APA
Wang, W., Bhattacharyya, S., Marangoni, R. G., Carns, M., Dennis-Aren, K., Yeldandi, A., Wei, J., & Varga, J. (2020). The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. Journal of Scleroderma and Related Disorders, 5(1), 40-50. https://doi.org/10.1177/2397198319865367
Vancouver
Wang W, Bhattacharyya S, Marangoni RG, Carns M, Dennis-Aren K, Yeldandi A, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. Journal of Scleroderma and Related Disorders. 2020;5(1):40-50. doi:10.1177/2397198319865367
BibTeX
@article{Wang2020,
author = {Wang, Wenxia and Bhattacharyya, Swati and Marangoni, Roberta Goncalves and Carns, Mary and Dennis-Aren, Kathleen and Yeldandi, Anjana and Wei, Jun and Varga, John},
title = {The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib},
journal = {Journal of Scleroderma and Related Disorders},
year = {2020},
volume = {5},
number = {1},
pages = {40--50},
doi = {10.1177/2397198319865367}
}
EUVIMED